fluticasone furoate and vilanterol inhalation powder (Breo Ellipta) (cont.)

Medical Author:
Medical and Pharmacy Editor:

PRESCRIPTION: yes

GENERIC AVAILABLE: no

STORAGE: Breo Ellipta should be kept at room temperature, 15 C to 30 C (59 F to 86 F) and stored in a dry place away from light.

PRESCRIBED FOR: Breo Ellipta is used for long-term treatment of COPD (emphysema or chronic bronchitis). Breo Ellipta is not used for acute episodes of bronchospasm or treatment of asthma.

DOSING: The recommended dose is one inhalation once daily by mouth. Following administration, the mouth should be rinsed thoroughly with water without swallowing to reduce risk of fungal infections.

DRUG INTERACTIONS: Ritonavir (Norvir), atazanavir (Reyataz), clarithromycin (Biaxin), indinavir (Crixivan), itraconazole (Sporanox), ketoconazole, nelfinavir (Viracept), and telithromycin (Ketek) may increase levels of fluticasone and vilanterol in the body by reducing the breakdown of fluticasone and vilanterol by liver enzymes. This may increase side effects of Breo Ellipta.

Beta blockers (for example, atenolol [Tenormin]) can block the effects of vilanterol and cause bronchospam in patients with COPD.

Combining or using Breo Ellipta within two weeks of stopping monoamine oxidase inhibitors (for example, phenelzine), tricyclic antidepressants (for example, amitriptyline [Endep, Elavil]), or other drugs that affect heart rate and rhythm, may increase risk of heart-related side effects.

Medically Reviewed by a Doctor on 6/12/2013


Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.


Back to Medications Index